AKRON — For the past decade, Dr. Judit E. Puskas, professor of polymer science at The University of Akron, has worked to develop a new and innovative breast prosthesis safer for implant patients than the current silicone variety.
With one in eight American women diagnosed with breast cancer each year – 70,000 of whom undergo mastectomies followed by breast reconstruction – Puskas says she felt driven and obligated to use her expertise as a polymer scientist to develop a superior prosthetic breast, one that would not force women back to the operating room for repeat surgeries in years following their initial breast reconstructions.
The documented 30 percent failure rate of the mainstay silicone gel implant due to ruptures, leakage and capsular contracture stunned Puskas and provoked her to come up with a solution.
Health Benefit Consultants, Share Your Expert Insights in Our Survey
WKYC-TV Website WKYC provides comprehensive media coverage of the business of health care in Cleveland. WKYC is also a MedCityNews syndication partner.
Her development – a soft and transparent thermoplastic elastomer breast implant with an antimicrobial coating to prevent infections – has received strong support from the research community in recent months.
The National Cancer Institute/U.S. National Institutes of Health awarded $231,725 in February 2010 to Puskas, who has partnered with Dr. Steven Schmidt, Summa Health System, to further develop a biocompatible nanocomposite as an alternative to silicone rubber for breast prosthetics.
Puskas, who serves as the research team’s principal investigator, is working with the proprietary polymer. The polymer is a new generation of the material used as the coating on the FDA-approved Taxus® Drug Eluting Stent.
As a postdoctoral researcher, Puskas helped develop the first-generation polymer – poly(styrene-b-isobutylene-b-styrene) block copolymer – with Dr. Joseph Kennedy, UA distinguished professor of polymer science and chemistry.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The new generation material and newly developed coatings ideally will improve implant function and healing. In addition to the NCI funding, the Austen BioInnovation Institute in Akron awarded $100,000 to support Puskas’ research.
During the project’s two-year period, Puskas and her team plan to synthesize the anocomposite at a lab-batch scale; evaluate its thermal, physical and mechanical properties; and establish its in vitro biocompatibility. “The ultimate goal of this research and development effort is to create prototype breast implants and prostheses for FDA approval,” Puskas says.
She is still hoping for additional grants of at least $2 million to get the implant into human trials in the next two years.
WKYC provides comprehensive media coverage of the business of health care in Cleveland. WKYC is also a MedCityNews syndication partner.
